ArticleNeurocritical care2026
Andexanet Alfa in Emergency Cranial Neurosurgical Procedures: A Bicentric Analysis of Efficacy and Safety.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Remote Ischemic Conditioning After Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis.Neurocritical care · 2026Pooled it
- Emergency reversal of Rivaroxaban with Andexanet alfa in a child with hemorrhagic brain metastasis from Wilms tumor.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFactor Xa inhibitors are widely used anticoagulants but are associated with a known risk of bleeding complications. In 2018, andexanet alfa was approved as an antidote for the reversal of apixaban and rivaroxaban, demonstrating high efficacy in controlling intracranial hemorrhage. However, data on its use prior to neurosurgical procedures remain limited. Here, we present our experience with andexanet alfa in patients undergoing emergency cranial neurosurgical procedures.
methodsHere, we present a case series based on a retrospective analysis conducted over a four-year period, identifying patients who underwent cranial neurosurgical procedures while on factor Xa inhibitors and treated with andexanet alfa at two tertiary academic neurosurgical centers in Germany. We reviewed demographic, clinical, and medical data, including age, sex, diagnosis, neurological status, laboratory results, surgical protocols, and imaging studies. The primary end points were (1) the efficacy of andexanet alfa in preventing secondary bleeding during or after surgery (hemostatic efficacy) and (2) its safety concerning ischemic events. Hemostatic efficacy was assessed via postoperative computed tomography scans performed six hours after surgery.
resultsA total of 29 patients (14 female, 15 male) underwent 34 neurosurgical procedures (18 burr-hole craniostomies [BHs] and 16 craniotomies [CRAs]). The patients' ages ranged from 55 to 94 years (mean 74.82 ± 10.65). The median Glasgow Coma Scale score was 7 at admission. In total, postoperative computed tomography scans revealed no or only minor hematoma in 94% of patients (BH in 94% vs. CRA in 94%; p > 0.99). Ischemic events occurred in 9 patients, including 8 cases of cerebral ischemia and one case of mesenteric ischemia (BH: 28%; CRA: 31%; p > 0.99). No cases of deep vein thrombosis or pulmonary embolism were recorded. The use of additional hemostatic agents was associated with the occurrence of ischemic events (p = 0.04, 95% confidence interval 1.11-122.77, odds ratio 11.7). Overall, in-hospital mortality was 28% in total.
conclusionsOur findings suggest that andexanet alfa is highly effective in preventing secondary bleeding during neurosurgery in patients on factor Xa inhibitors. However, the risk for ischemic events must be carefully considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.